A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

Phillip B. Donenberg net worth and biography

Phillip Donenberg Biography and Net Worth

Director of Taysha Gene Therapies

Phillip B. Donenberg CPA serves as Independent Director of the Company. Mr. Donenberg is senior vice president and chief financial officer of Project Jaguar LLC, an early-stage gene therapy company, and has served in such role since February 2020. From July 2018 to November 2018, Mr. Donenberg served as the chief financial officer and senior vice president of Assertio Therapeutics, Inc. (Nasdaq: ASRT), a pharmaceutical company. Previously, Mr. Donenberg served at AveXis, Inc. (now a Novartis company), a gene therapy company, as the senior vice president and chief financial officer from October 2017 to June 2018 and as vice president, corporate controller of AveXis, Inc. from September 2016 to October 2017. He was the chief financial officer of RestorGenex Corporation from May 2014 to January 2016, when RestorGenex merged with Diffusion Pharmaceuticals LLC, a pharmaceutical company, and served as the merged company’s consultant chief financial officer until September 2016, and the chief financial officer of 7wire Ventures LLC, an early stage healthcare venture fund, from September 2013 to May 2014. Prior to that time, Mr. Donenberg served as the chief financial officer of BioSante Pharmaceuticals, Inc. from July 1998 to June 2013, when BioSante merged with ANIP Pharmaceuticals, Inc. Mr. Donenberg also has experience serving on the boards of directors of privately held companies.

How do I contact Phillip B. Donenberg?: The corporate mailing address for Mr. Donenberg and other Taysha Gene Therapies executives is 2280 Inwood Road, DALLAS TX, 75235. Taysha Gene Therapies can also be reached via phone at 214-612-0000 and via email at [email protected]. Learn More on Phillip B. Donenberg's contact information.
Has Phillip B. Donenberg been buying or selling shares of Taysha Gene Therapies?: Phillip B. Donenberg has not been actively trading shares of Taysha Gene Therapies within the last three months. Most recently, on Wednesday, February 2nd, Phillip B. Donenberg bought 3,000 shares of Taysha Gene Therapies stock. The stock was acquired at an average cost of $7.78 per share, with a total value of $23,340.00. Learn More on Phillip B. Donenberg's trading history.
Who are Taysha Gene Therapies' active insiders?: Taysha Gene Therapies' insider roster includes Kamran Alam (CFO), Phillip Donenberg (Director), Paul Manning (Director), Sean Nolan (Director), and R.A. Session, II (CEO). Learn More on Taysha Gene Therapies' active insiders.
Are insiders buying or selling shares of Taysha Gene Therapies?: In the last twelve months, Taysha Gene Therapies insiders bought shares 5 times. They purchased a total of 17,405,000 shares worth more than $15,736,400.00. In the last twelve months, insiders at the sold shares 4 times. They sold a total of 419,689 shares worth more than $351,334.11. The most recent insider tranaction occured on November, 17th when Major Shareholder Paul B Manning bought 100,000 shares worth more than $163,000.00. Insiders at Taysha Gene Therapies own 2.3% of the company. Learn More about insider trades at Taysha Gene Therapies.
Information on this page was last updated on 11/17/2023.

Phillip B. Donenberg Insider Trading History at Taysha Gene Therapies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/2/2022	Buy	3,000	$7.78	$23,340.00

Phillip B. Donenberg Buying and Selling Activity at Taysha Gene Therapies

Taysha Gene Therapies Company Overview

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Today's Range

Now: $2.27

$2.15

$2.43

50 Day Range

MA: $2.56

$1.46

$3.25

2 Week Range

Now: $2.27

$0.50

$3.89

Volume

1,790,252 shs

Average Volume

2,182,185 shs

Market Capitalization

$424.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.29

SHOCKING Crypto Leak…

From Crypto 101 Media | Ad